Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome

Sarepta Therapeutics Surges 20% On No News

Sarepta Therapeutics Surges 20% On No News

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by 20 percent at one point early Friday morning on no confirmed news reports.

Sarepta's investor relations website showed no new updates. Meanwhile, Twitter users were sharing various theories to explain the unexpected surge in Sarepta's stock.

As a reminder, the U.S. Food and Drug Administrated decided in late April that the company's drug for the treatment of Duchenne muscular dystrophy (DMD) was not effective. A final vote to approve or decline the drug, eteplirsen, is scheduled for May 26.

The stock traded recently at $18.99, up 7.9 percent in Friday's pre-market session.

Posted-In: Duchenne Muscular Dystrophy eteplirsen Food and Drug AdministrationNews Health Care Pre-Market Outlook Movers General


Related Articles (SRPT)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Bidding Prices For Yahoo's Internet Assets Notably Below Prior Expectations

Foot Locker Reports Inline EPS, But Shares Down